Literature DB >> 6303590

The World Health Organization's Histological Classification of Lung Tumors: a comparison of the first and second editions.

L H Sobin.   

Abstract

Revision of the WHO Histological Classification of Lung Tumors of 1967 has resulted in the 1981 publication of the second edition. The main features of the revisions have been summarized. Squamous cell carcinoma (epidermoid carcinoma) has the same definition as in the original version, ie, the identification of keratin and/or intercellular bridges by light microscopy. Three degrees of histological differentiation have been described. Dysplasia and carcinoma in situ have been discussed. Small cell carcinoma has been divided into oat cell carcinoma, an intermediate cell type and a category for oat cell carcinomas combined with other major types. Adenocarcinoma includes the acinar, papillary and bronchiolo-alveolar forms, and the solid carcinomas with mucus formation (previously part of the large cell carcinoma group). A number of less common tumors and tumor-like lesions have been defined. None of the changes in the revision are considered to be a major departure from the original classification. This is intended in order to preserve comparability between data collected with each edition. The need for utilizing standardized nomenclature, diagnostic criteria, and tabulation formats is stressed.

Entities:  

Mesh:

Year:  1982        PMID: 6303590

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  9 in total

1.  Association of SIRT1 and HMGA1 expression in non-small cell lung cancer.

Authors:  Shuang-Yan Lin; Fang Peng
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

2.  Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.

Authors:  R J Slebos; S G Evers; S S Wagenaar; S Rodenhuis
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

3.  p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer.

Authors:  F J Vega; P Iniesta; T Caldés; A Sanchez; J A López; C de Juan; E Diaz-Rubio; A Torres; J L Balibrea; M Benito
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients.

Authors:  G-B Qiao; Y-L Wu; X-N Yang; W-Z Zhong; D Xie; X-Y Guan; D Fischer; H-C Kolberg; S Kruger; H-W Stuerzbecher
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

Review 5.  Combined small-cell lung carcinoma.

Authors:  Jing Qin; Hongyang Lu
Journal:  Onco Targets Ther       Date:  2018-06-19       Impact factor: 4.147

6.  Clinical significance of the expression of miRNA-21, miRNA-31 and miRNA-let7 in patients with lung cancer.

Authors:  Sheng Wang; Zigui Wang; Qiming Wang; Yun Cui; Suxia Luo
Journal:  Saudi J Biol Sci       Date:  2018-12-17       Impact factor: 4.219

7.  BLNIMDA: identifying miRNA-disease associations based on weighted bi-level network.

Authors:  Junliang Shang; Yi Yang; Feng Li; Boxin Guan; Jin-Xing Liu; Yan Sun
Journal:  BMC Genomics       Date:  2022-10-05       Impact factor: 4.547

8.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

Authors:  P Korkolopoulou; L Kaklamanis; F Pezzella; A L Harris; K C Gatter
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

9.  Relationship between 3p deletions and telomerase activity in non-small-cell lung cancer: prognostic implications.

Authors:  P Iniesta; R González-Quevedo; A Morán; C García-Aranda; C de Juan; A Sánchez-Pernaute; A Torres; E Díaz-Rubio; J L Balibrea; M Benito
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.